Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AbbVie

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Paychex

Rollins

Schwab US Dividend Equity ETF

Snap-on

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF, with a few minor twists. The portfolio fell by 0.57% in August, outperforming the S&P 500 by 1.02%. Year-to-date, the portfolio is up 14.07%. Since inception, the portfolio is generating 3.95% of alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Closing In On A Historic First Year

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Expands Merck's ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older.

European Commission Expands Merck's ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Merck & Co., Inc. (NYSE:MRK ) Citi 18th Annual BioPharma Conference September 6, 2023 1:50 PM ET Company Participants Marjorie Green - SVP and Head of Late Stage Oncology, Global Clinical Development Conference Call Participants Andrew Baum - Citi Andrew Baum So delighted to introduce our next speaker, Dr. Marjorie Green at Merck, who heads Oncology Development. Marjorie came five months ago from Seagen.

Merck & Co., Inc. (MRK) Citi 18th Annual BioPharma Conference (Transcript)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics.

Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference.

Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

AstraZeneca

Bristol-Myers

Johnson & Johnson

Eli Lilly

Pfizer

The Medicare Modernization Act that established the Part D program in 2003 prohibited the federal government from negotiating drug prices with manufacturers. The Inflation Reduction Act, signed into law by President Biden last year, allows Medicare to start negotiating the prices it will pay for some widely used drugs.

8 Pharma Stocks Affected by New Drug Price Negotiation Rules

Moderna

Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.

Judge withdraws from Medicare drug price case after stock ownership is revealed

Astellas Pharma Inc

Amgen

Horizon Pharma

Novo Nordisk

Novartis

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Why Is Merck (MRK) Up 4.3% Since Last Earnings Report?

Coca-Cola

We compare their current multiples with the historical ones in the sections below to better gauge their valuations.

Should You Pick Merck Stock Over Coca-Cola?

Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.

Medicare drug price negotiations may have a muted impact on drugmakers in the near term

Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.

Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer

Costco

Duke Energy

Kellogg

Monster Beverage

Procter & Gamble

Phillips 66

If there's any one theme that supports the concept of safe stocks to buy, it's ambiguity. At first glance, Federal Reserve Chair Jerome Powell recently clarified that while inflation is finally moving in the right direction, policymakers still have much work to do.

Steady Eddies: 7 Unshakeable Stocks for Any Type of Market

We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these.

10 Drugs Selected for Medicare Price Reduction

Eli Lilly's Mounjaro is shaping up to be a long-term driver of earnings growth. The same is true for Merck's Keytruda, a medication for treating certain cancers.

Better Pharma Growth Stock: Eli Lilly vs. Merck

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts

Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications for pharmaceutical companies, taxpayers and patients. The selected drugs are the Bristol Myers Squibb Co. BMY, -0.71% blood thinner Eliquis, Boehringer Ingelheim's heart failure drug Jardiance, Johnson and Johnson JNJ, -1.18% blood thinner Xarelto, Merck & Co. Inc. MRK, -1.16% diabetes drug Januvia, AstraZeneca AZN, +0.57% heart failure drug Farxiga, Novartis AG NVS, +0.55% heart failure drug Entresto, Amgen Inc. AMGN, +0.07% rheumatoid arthritis drug Enbrel, AbbVie Inc. ABBV, +0.50% blood cancer drug Imbruvica, Johnson and Johnson psoriasis treatment Stelara, and Novo Nordisk NVO, +0.57% insulin Fiasp.

Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--EC Approves KEYTRUDA Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction.

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Citi 18th Annual BioPharma Conference.

Merck to Participate in the Citi 18th Annual BioPharma Conference

Alphabet

Dow Jones leader Merck, along with Google-parent Alphabet stock and Mastercard, are in or near buy zones in today's stock market action.

Dow Jones Drug Giant Merck, Google Stock, Mastercard In Or Near Buy Zones

With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and Eisai have decided to close the study.

Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study

Regeneron Pharmaceuticals

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

Oncology Market's Huge Potential Puts These Stocks in Focus

Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head and neck cancer after it didn't result in an overall survival benefit for patients. In a statement, the companies said the Phase 3 LEAP 010 trial evaluated Merck's anti-PD-1 therapy Keytruda together with Eisai's Lenvima, an orally available multiple receptor tyrosine kinase inhibitor (TKI) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Merck and Eisai cull late-stage study for head and neck cancer therapy

Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. 4523, -1.23% ESAIY, -1.95% said Friday a late-stage trial of a treatment for head and neck cancer failed to meet its main goals and the companies have decided to shut it down.

Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals

Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and neck cancer after an interim analysis showed it failed to prolong lives of patients.

News for Merck Stock (MRK)